Search results
Cardiac Troponins in Kidney Disease
Added:
9 months ago
Review Article
Added:
4 months ago
Added:
6 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus…
View more
Added:
1 year ago
Host, Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by PI, Dr Derek Chew (Monash Heart and Victorian Heart Institute, AU) to discuss the findings from the RAPIDxAI trial, which aims to improve the assessment of suspected cardiac chest pain in emergency departments (ED) using a machine-learning algorithm that will interpret high-sensitivity troponin test…
View more
Added:
3 weeks ago
Source:
Arrhythmia Academy
Atrial fibrillation (AF), particularly when paroxysmal and asymptomatic, often goes undiagnosed, increasing the risk of stroke. A recent trial investigated whether remote screening with a commercially available smartwatch could enhance the detection of new-onset AF in an older population with an elevated risk of stroke.²Mechanism of ApplicationThe intervention utilised a smartwatch equipped with…
View more
Added:
1 month ago
Source:
Interventional Cardiology Review Journal
For patients with atrial fibrillation (AF) at high risk for both stroke and bleeding, catheter-based left atrial appendage closure (LAAC) was not found to be non-inferior to physician-directed best medical care, according to the results of the CLOSURE-AF trial.¹MethodologyThe multicentre, randomised CLOSURE-AF trial was conducted in Germany to assess the effectiveness of LAAC compared with best…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9…
View more
Added:
1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel…
View more
Added:
1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial…
View more